AiViva BioPharma

Executive Summary

AiViva BioPharma is a clinical-stage biotechnology company developing novel therapeutics using its proprietary JEL Technology, designed to prolong drug effects and improve benefit-risk profiles. Founded in 2015 and headquartered in Newport Beach, California, the company focuses on unmet medical needs across dermatology, ophthalmology, oncology, and urology. With a Phase 1 stage pipeline, AiViva aims to address significant market opportunities in drug delivery optimization. The company's private status and lack of disclosed funding details suggest early-stage development, making clinical progress and strategic partnerships critical for value creation.

Upcoming Catalysts (preview)

• TBDPhase 1/2 clinical data readout for lead JEL-based candidate40% success
• TBDPartnership or licensing agreement with a larger pharmaceutical company30% success
• TBDSeries A or B financing round to fund pipeline advancement50% success